Our bioethics consultation services address issues at the intersection of ethics, law, health research, and clinical care. Current Health Technology Assessments (HTA) are not well equipped to assess complex technologies such as gene therapies or rare diseases. In particular, they lack the attention to the diversity in patient characteristics and patient preferences, the limited consideration of context and implementation issues, and missing strategies to integrate all these aspects into a comprehensive assessment. We help our clients develop concepts and methods for HTA to enable a patient-centered, integrated assessment of the effectiveness, and the economic, social, cultural and ethical issues of complex technologies that takes context and implementation into account. By focusing on an integrated assessment, we match the need of policy-makers who prefer this to dealing with scattered information on innovative and complex technologies.
More specifically, we adapt and develop methods and concepts:
- to assess the effectiveness and economic, social, cultural, and ethical issues of complex technologies
- to elicit patient preferences and patient-specific moderators of treatment
- to include context, setting, and implementation
- to integrate these issues into a patient-centered, comprehensive assessment of complex technologies
Our services help clients decide how to respond to ethical concerns that may occur over the course of a trial or benefit assessment. In addition, we provide independent and informed advice for ethically questionable research proposals and provide commentary and explanations to the public of research performed, and in some cases provide education to client employees.